Publications by authors named "P T Ravichandran"
Tyrosine kinase inhibitors (TKIs) serve to inhibit the phosphorylation cascade that usually leads to abnormal processes such as vascular leakage and tumorigenesis. Within retinal diseases specifically, dysregulation of the vascular endothelial growth factor receptor tyrosine kinases can lead to age-related macular degeneration and diabetic macular edema. These diseases have a growing prevalence and are leading causes of vision loss.
View Article and Find Full Text PDFDerangements in pharmacokinetics and pharmacodynamics (PK/PD) of burn patients are poorly understood and lacking consistent data. This leads to an absence of consensus regarding pharmacologic management of burn patients, complicating their care. In order to effectively manage burn critical illness, knowledge of pharmacologic parameters and their changes is necessary.
View Article and Find Full Text PDFArticle Synopsis
- Visium is a transcriptomics assay from 10x Genomics that struggles with overlapping tissue capture areas, needing better tools for combining data from multiple images effectively.
- A new R/Bioconductor package called visiumStitched has been developed to stitch these images together, allowing for more complex analysis while preserving data from overlapping areas.
- While visiumStitched simplifies the handling of multi-capture study designs, it does have some limitations regarding data accuracy when aligning with other reference atlases.
Background: In 2022, India's national tuberculosis (TB) elimination program (NTEP) commissioned a national level evaluation of active case finding (ACF) for TB to guide evidence-based strategic planning. As part of this evaluation, based on secondary data analysis we observed that the quality of ACF was suboptimal in 2021. Hence, this study aimed to understand the enablers, barriers, and suggested solutions to improve ACF for TB in India from NTEP staff (provider) perspective.
View Article and Find Full Text PDFArticle Synopsis
- * It uses vorolanib, which blocks all forms of VEGF to reduce abnormal blood vessel growth and leakage in the eye.
- * The Durasert delivery system allows for a steady release of vorolanib directly into the eye, leading to less frequent doctor visits and a safer, more convenient treatment option.